SONN•benzinga•
Sonnet BioTherapeutics Announces Safety Review Results Of SON-1010 In Combination With Trabectedin For Advanced Soft Tissue Sarcomas, Showing No Unexpected Toxicities And Clinical Benefit In 83% Of Patients, Paving The Way For Full Enrollment In Phase 1 S
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga